Dynavax Technologies (NASDAQ:DVAX) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a $29.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com cut Dynavax Technologies from a buy rating to a hold rating in a research note on Tuesday, May 28th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $25.33.

Dynavax Technologies Stock Down 1.2 %

Shares of NASDAQ:DVAX opened at $11.23 on Friday. The firm has a market capitalization of $1.47 billion, a PE ratio of 187.17 and a beta of 1.20. Dynavax Technologies has a 1 year low of $10.48 and a 1 year high of $15.15. The company has a debt-to-equity ratio of 0.36, a current ratio of 15.20 and a quick ratio of 14.10. The firm’s 50-day moving average is $11.54 and its two-hundred day moving average is $12.48.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $50.79 million for the quarter, compared to analysts’ expectations of $51.98 million. Dynavax Technologies had a return on equity of 1.52% and a net margin of 3.91%. Analysts predict that Dynavax Technologies will post 0.12 EPS for the current year.

Insider Buying and Selling

In other Dynavax Technologies news, Director Francis Cano sold 3,615 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.93, for a total value of $43,126.95. Following the sale, the director now directly owns 36,905 shares of the company’s stock, valued at approximately $440,276.65. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.98% of the stock is owned by insiders.

Institutional Trading of Dynavax Technologies

A number of institutional investors have recently bought and sold shares of DVAX. Advisor Resource Council acquired a new stake in shares of Dynavax Technologies during the 4th quarter worth about $144,000. China Universal Asset Management Co. Ltd. purchased a new position in Dynavax Technologies in the fourth quarter valued at approximately $209,000. AlphaMark Advisors LLC acquired a new stake in Dynavax Technologies during the fourth quarter worth approximately $230,000. Natixis Advisors L.P. purchased a new stake in shares of Dynavax Technologies during the 3rd quarter worth approximately $255,000. Finally, Duality Advisers LP acquired a new position in shares of Dynavax Technologies in the 1st quarter valued at $227,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.